- Trial phase
- Phase 1c (initiated 2019, no reported results)
- Time to market
- Uncertain; the program is in early-stage development under the FDA Animal Rule pathway. No pivotal or registrational trials have been announced.
- Why 3/10
- RiVax has no hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) scheduled in the next ~12 months. The program is in preclinical/early-stage development under the FDA Animal Rule pathway, with no active clinical trial results reported since the Phase 1c was initiated in 2019. The stock trades around $0.34 with a ~$8M market cap, and the company's primary near-term focus appears to be its HyBryte Phase 3 program and SGX945 orphan drug designation.
RiVax is a biodefense vaccine with no near-term binary catalyst. The program has orphan drug designation and has shown positive preclinical correlates of protection in non-human primate ricin challenge studies, but no active clinical trial results have been reported since the Phase 1c was initiated in late 2019. Soligenix's cash position of roughly $9.0M as of September 30, 2026, is limited, and the company's primary focus appears to be its HyBryte CTCL program and SGX945 for Behcet's disease. Watch for any new NIAID/BARDA contract awards or Animal Rule meeting outcomes that could re-energize the program.
Price Chart
Executive Summary
RiVax is Soligenix's proprietary ricin toxin vaccine, one of the most advanced ricin vaccine candidates in the world. It has completed Phase 1 and Phase 1b human clinical trials demonstrating safety and immunogenicity, and a Phase 1c trial of a thermostable formulation was initiated in 2019. The program has FDA Orphan Drug Designation and is being developed under the FDA Animal Rule for biodefense stockpiling, with NIAID contract funding totaling up to $24.7 million. However, no clinical trial results have been reported since 2019, and the company's recent Q3 2026 financial results did not mention RiVax progress, suggesting the program is on the back burner while Soligenix focuses on its HyBryte and SGX945 rare-disease programs. Soligenix had roughly $9.0M in cash as of September 30, 2026, and the stock trades around $0.34 with a market cap of about $8M.
How It Works
RiVax is a vaccine designed to protect against ricin toxin, a lethal poison derived from castor beans that can be used as a biological weapon. It works by training the immune system to recognize and neutralize the ricin toxin's A-chain, the part that enters cells and causes toxicity. The vaccine uses a modified, non-toxic version of the ricin A-chain protein (an antigen) combined with an aluminum hydroxide adjuvant to boost the immune response. A thermostable (heat-stable, freeze-dried) formulation is being developed so the vaccine can be stockpiled and used without requiring continuous refrigeration.
Trial Status
RiVax has completed Phase 1 and Phase 1b clinical trials (2010-2012) showing safety and immunogenicity with alum adjuvant. A Phase 1c trial of a lyophilized (freeze-dried, thermostable) formulation was initiated in December 2019, but no results from that trial have been publicly reported. Preclinical studies published through 2022 demonstrated correlates of immune protection and up to 100% survival in non-human primates challenged with lethal aerosolized ricin. The program is being developed under the FDA Animal Rule, which allows efficacy data from animal models to support approval when human efficacy trials are not feasible.
The Two-Sided Case
Upcoming Catalysts
- Any new NIAID/BARDA contract award or option exercise for RiVax development
- Potential FDA Animal Rule meeting or guidance on the approval pathway
- Any reported results from the Phase 1c lyophilized formulation trial
- Government biodefense stockpiling decisions that could include ricin countermeasures
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Soligenix, Inc. PRESS-RELEASE SNGX ·Originating report